Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1455211

Remodeling of tumour microenvironment: Strategies to Overcome Therapeutic Resistance and Innovate Immunoengineering in Triple-Negative Breast Cancer

Provisionally accepted
Desh D. Singh Desh D. Singh 1Shafiul Haque Shafiul Haque 2Ihn Han Ihn Han 3Dharmendra K. Yadav Dharmendra K. Yadav 4*
  • 1 Amity University Jaipur, Jaipur, Rajasthan, India
  • 2 Jazan University, Jizan, Saudi Arabia
  • 3 Plasma Bioscience Research Center, Kwangwoon University, Seoul, Republic of Korea
  • 4 College of Pharmacy, Gachon University of Medicine and Science, Incheon, Republic of Korea

The final, formatted version of the article will be published soon.

    Triple-negative breast cancer (TNBC) stands as the most complex and daunting subtype of breast cancer affecting women globally. Regrettably, treatment options for TNBC remain limited due to its clinical complexity. However, immunotherapy has emerged as a promising avenue, showing success in developing effective therapies for advanced cases and improving patient outcomes.Improving TNBC treatments involves reducing side effects, minimizing systemic toxicity, and enhancing efficacy. Unlike traditional cancer immunotherapy, engineered nonmaterial's can precisely target TNBC, facilitating immune cell access, improving antigen presentation, and triggering lasting immune responses. Nanocarriers with enhanced sensitivity and specificity, specific cellular absorption, and low toxicity are gaining attention. Nanotechnology-driven immunoengineering strategies focus on targeted delivery systems using multifunctional molecules for precise tracking, diagnosis, and therapy in TNBC. This study delves into TNBC's tumour microenvironment (TME) remodeling, therapeutic resistance, and immunoengineering strategies using nanotechnology.

    Keywords: Triple negative breast cancer, Immunotherapy, Tumor Microenvironment, Drug Resistance, Nanomedicine

    Received: 26 Jun 2024; Accepted: 31 Oct 2024.

    Copyright: © 2024 Singh, Haque, Han and Yadav. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Dharmendra K. Yadav, College of Pharmacy, Gachon University of Medicine and Science, Incheon, Republic of Korea

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.